ID   LO-CD2a
AC   CVCL_A6CS
SY   LO-CD2A; Lo-CD2a; LO-CD2-act; Lo-CD2-act; BTI-322
DR   ABCD; ABCD_AH427
DR   ATCC; HB-11423
DR   Wikidata; Q107115673
RX   CelloPub=CLPUB00617;
RX   Patent=US6849258;
RX   Patent=US7592006;
RX   PubMed=7627995;
RX   PubMed=8757956;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11423.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized siplizumab (MEDI-507) therapeutic antibody.
CC   Monoclonal antibody isotype: IgG2b, kappa.
CC   Monoclonal antibody target: UniProtKB; P06729; Human CD2.
OX   NCBI_TaxID=10116; ! Rattus norvegicus (Rat)
HI   CVCL_7675 ! IR983F
CA   Hybridoma
DT   Created: 20-05-21; Last updated: 21-03-23; Version: 4
//
RX   CelloPub=CLPUB00617;
RA   Xia H.-Z., Ravoet A.-M., Latinne D., Ninane J., De Bruyere M., Sokal G.,
RA   Bazin H.;
RT   "Rat monoclonal antibodies specific for human T lymphocytes.";
RL   (In) Rat hybridomas and rat monoclonal antibodies; Bazin H. (eds.); pp.309-322; CRC Press; Boca Raton (1990).
//
RX   Patent=US6849258;
RA   Bazin H., Latinne D., Kaplan R., Kieber-Emmons T., Postema C.E.,
RA   White-Scharf M.E.;
RT   "LO-CD2a antibody and uses thereof for inhibiting T cell activation
RT   and proliferation.";
RL   Patent number US6849258, 01-Feb-2005.
//
RX   Patent=US7592006;
RA   Bazin H., Latinne D.;
RT   "Composition comprising the LO-CD2a antibody.";
RL   Patent number US7592006, 22-Sep-2009.
//
RX   PubMed=7627995; DOI=10.1007/BF01525389;
RA   Bombil F., Kints J.-P., Havaux X., Scheiff J.-M., Bazin H., Latinne D.;
RT   "A rat monoclonal anti-(human CD2) and L-leucine methyl ester impacts
RT   on human/SCID mouse graft and B lymphoproliferative syndrome.";
RL   Cancer Immunol. Immunother. 40:383-389(1995).
//
RX   PubMed=8757956; DOI=10.1093/intimm/8.7.1113;
RA   Latinne D., De La Parra B., Nizet Y., Cornet A., Giovino-Barry V.,
RA   Monroy R.L., White-Scharf M.E., Bazin H.;
RT   "An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of
RT   CD2+ human T cells in vitro.";
RL   Int. Immunol. 8:1113-1119(1996).
//